EGFR and non-small cell lung carcinoma: Though the majority of NSCLC patients were EGFR wild type (EGFR-WT), there are still 3-15% of them respond to EGFR-TKIs with a disease control rate (DCR) of 40-60% [8, 11-13], which suggests that a subgroup of EGFR-WT patients benefit from EGFR inhibitor treatment.